Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:8/28/2015)... 28 de agosto de 2015   Royal ... participación en el  Congreso de la ESC de ... recientes y novedosas, entre ellas HeartModel A.I.  , ... personas y la tecnología con los protocolos de ... los tratamientos y permitir atención en el hogar. ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015 DURECT ... is scheduled to present at three upcoming healthcare conferences.  ... President and CEO, will present at the Rodman & ... a.m. Eastern time. The conference is being held at ... City . A live audio webcast of the ...
(Date:8/27/2015)... PLYMOUTH MEETING, Pa. , Aug. 27, 2015 /PRNewswire-USNewswire/ ... is decommissioning the Da Vinci S™ surgical robot, hospitals ... robot replacement plans. They also need to see where ... right procedures on the right patients? Have they adopted ... their robotic surgery program in the future? ...
Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5DURECT to Participate in Upcoming Healthcare Conferences 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... CVS Caremark (NYSE: CVS ) today ... of CVS/pharmacy effective October 1, 2011.  With more than ... and Puerto Rico, CVS/pharmacy is one of the largest ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) Cosby, 52, most recently served as ...
... Oncobiologics, Inc. and Fox Chase Cancer Center ... next-generation bi-specific antibody cancer platform with enhanced therapeutic ... is designed to handle multiple targets, representing a ... is now underway, with preclinical studies expected in ...
Cached Medicine Technology:CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 2CVS Caremark Appoints Mark S. Cosby as President of CVS/pharmacy 3Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 2Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy Platform 3
(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is ... with their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known ... stroke. They believe that together, a difference can be made. Walkers can participate in ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor ... Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an official ... , “With the help of the medical community and the University of Illinois at ...
(Date:8/28/2015)... ... 2015 , ... Saint Petersburg, FL —Pocket Protein™, a protein ... sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that never ... Choice Awards. , Five consumer packaged goods (CPG) products were selected by the ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... specialist, Dr. James Strawbridge, gives a new approach on solutions in his new ... with the employer and employees getting together for meaningful group meetings. "This would ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... right form of counseling can reverse seasonal ... stress-related ... of reproductive medical specialists are encouraged by new research,pointing toward ... -- the year-end holiday blues, which doctors say can,actually have ...
... The Centers for Disease,Control and Prevention (CDC), ... in Infection Control and Epidemiology (APIC), is,developing ... (HAI) data from existing commercial,software systems to ... vendor-neutral solution enables hospitals to provide data ...
... Directors of,MSA (NYSE: MSA ) has elected William ... company,s President and Chief Operating Officer,and will succeed John ... retirement in May of 2008. Mr. Lambert, 49, joined ... http://www.newscom.com/cgi-bin/prnh/20071213/NETH072 ), "The Board of Directors and ...
... Associates, Inc. ("MQ,Associates" or the "Company"), and MedQuest, ... announced today that it completed,its tender offers (the ... of the,outstanding $136 million aggregate principal amount at ... (CUSIP No. 55345RAC2) (the "Discount Notes"),issued by MQ ...
... out to patients in ... need of care worldwide, EL SEGUNDO, Calif., ... life-saving by 16 year-old,Juan Carlos and his family living in Guayaquil, Ecuador. ... days away from dying.,This past December, DaVita -- one of the nation,s ...
... Richardson is a psychiatrist with Parkwood Hospital, part of ... the Schulich School of Medicine & Dentistry at The ... random, national survey of more than a thousand Canadian ... below the age of 65 and had served with ...
Cached Medicine News:Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 2Health News:Doctors: Talk Therapy Newest Hope for Treating One Physical Side Effect of Holiday Blues 3Health News:CDC Uses New Technical Approach to Enable Hospital Reporting of Healthcare-Associated Infections 2Health News:MSA Elects William M. Lambert to Board 2Health News:MSA Elects William M. Lambert to Board 3Health News:MQ Associates, Inc. Announces Expiration of its Tender Offers for its 12 1/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Medquest, Inc.'s 11 7/8% Senior Subordinated Notes Due 2012 (CUSIP No. 58505DAD1) 2Health News:MQ Associates, Inc. Announces Expiration of its Tender Offers for its 12 1/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Medquest, Inc.'s 11 7/8% Senior Subordinated Notes Due 2012 (CUSIP No. 58505DAD1) 3Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 2Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 3
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the qualitative detection of group A streptococcal antigen from throat swabs....
For the measurement of vaginal pH as part of a self examination programme to help reduce the risk of pre-term birth...
Medicine Products: